Get started
Author

Albert Hallsworth

Observed names: A. Hallsworth, Albert E. Hallsworth, Hallsworth, Albert E.
OpenAlex ID: A5046795271
The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma
2012 · Teeara Berry, William Luther, et al. · Cancer Cell · 324
PDF
Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease
2014 · Rebecca M. Hill, Sanne Kuijper, et al. · Cancer Cell · 210
PDF
CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs
2012 · Mike I. Walton, Paul D. Eve, et al. · Clinical Cancer Research · 92
Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma
2020 · Evon Poon, Tong Liang, et al. · Journal of Clinical Investigation · 68
PDF
Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma
2015 · M. Emmy M. Dolman, Evon Poon, et al. · Clinical Cancer Research · 65
In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis
2019 · Orli Yogev, Gilberto S. Almeida, et al. · Cancer Research · 63
PDF
Application of Meso Scale Technology for the Measurement of Phosphoproteins in Human Tumor Xenografts
2007 · Sharon M. Gowan, Anthea Hardcastle, et al. · Assay and Drug Development Technologies · 59
p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance
2016 · Orli Yogev, Karen Barker, et al. · Cancer Research · 46
Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage
2021 · Pietro Carotenuto, Francesco Amato, et al. · Nature Communications · 39
PDF
MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma
2020 · David King, Xiao Dun Li, et al. · Oncotarget · 37
PDF
Evaluation of Clinically Translatable MR Imaging Biomarkers of Therapeutic Response in the TH-MYCNTransgenic Mouse Model of Neuroblastoma
2012 · Yann Jamin, Elizabeth R. Tucker, et al. · Radiology · 37
miRNA Expression Profiling of the Murine TH-MYCN Neuroblastoma Model Reveals Similarities with Human Tumors and Identifies Novel Candidate MiRNAs
2011 · Marta Terrile, Kenneth Bryan, et al. · PLoS ONE · 35
PDF
Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736
2020 · Andrew S. Moore, Amir Faisal, et al. · Blood Advances · 27
PDF
Molecular and In Vivo Characterization of Cancer-Propagating Cells Derived from MYCN-Dependent Medulloblastoma
2015 · Zai Ahmad, Lukasz Jasnos, et al. · PLoS ONE · 24
PDF
Identification of ovarian high-grade serous carcinoma cell lines that show estrogen-sensitive growth as xenografts in immunocompromised mice
2020 · Alexis De Haven Brandon, Gary Box, et al. · Scientific Reports · 23
PDF
Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 In Vivo
2022 · Rosemary Huckvale, Alice C. Harnden, et al. · Journal of Medicinal Chemistry · 17
Intrinsic Susceptibility MRI Identifies Tumors with ALKF1174L Mutation in Genetically-Engineered Murine Models of High-Risk Neuroblastoma
2014 · Yann Jamin, Laura Glass, et al. · PLoS ONE · 17
PDF
Pre-clinical imaging of transgenic mouse models of neuroblastoma using a dedicated 3-element solenoid coil on a clinical 3T platform
2017 · Gilberto S Almeida, Rafal Panek, et al. · British Journal of Cancer · 11
PDF
Response of GEM models of neuroblastoma to cabozantinib assessed by multiparametric magnetic resonance imaging
2025 · Gilberto S. Almeida, Philippa King, et al. · Neoplasia · 5
Discovery and validation of biomarkers to support clinical development of NXP800: A first-in-class orally active, small-molecule HSF1 pathway inhibitor
2022 · P. Workman, P.A. Clarke, et al. · European Journal of Cancer · 4
PDF
Correction: MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma
2023 · David King, Xiao Dun Li, et al. · Oncotarget · 2
PDF
Data from CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs
2023 · Mike I. Walton, Paul D. Eve, et al. · 1
Abstract 1010: A study of combinatorial growth inhibition, cell death and DNA damage repair caused by CHK1 inhibitor SRA737 and WEE1 inhibitor adavosertib in TP53 mutated cell lines
2021 · Adam Stewart, Lisa Pickard, et al. · Cancer Research · 1
Hg-67preclinical Efficacy of Alk2 Inhibitors in Acvr1 Mutant Dipg
2016 · Diana Carvalho, Kathryn Taylor, et al. · Neuro-Oncology · 1
Data from In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis
2023 · Orli Yogev, Gilberto S. Almeida, et al.
Works count: 88
Citation count: 1,208
H-index: 17
I10-index: 18
Year
Topic
Type